Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from 3-D Matrix ( (JP:7777) ).
3-D Matrix, Ltd. has achieved a significant breakthrough in cardiac regenerative therapy through its collaborative research with Harvard University, which was published in the journal Science. The study demonstrated that the company’s self-assembling peptide, RADA16, can suppress arrhythmogenic automaticity in iPSC-derived cardiomyocytes and enhance their integration with host cardiac tissue, potentially accelerating the practical application of iPSC-based therapies for heart disease and advancing regenerative medicine for other tissues requiring vascularization.
The most recent analyst rating on (JP:7777) stock is a Hold with a Yen339.00 price target. To see the full list of analyst forecasts on 3-D Matrix stock, see the JP:7777 Stock Forecast page.
More about 3-D Matrix
3-D Matrix, Ltd. is a company engaged in the development of medical products based on proprietary self-assembling peptide technology, focusing on regenerative medicine through collaborations with leading academic institutions worldwide.
Average Trading Volume: 4,268,393
Technical Sentiment Signal: Buy
Current Market Cap: Yen31.64B
Find detailed analytics on 7777 stock on TipRanks’ Stock Analysis page.